INFLUENZA & RESPIRATORY

 

APRIL 1-4, 2024
WALTER E CONVENTION CENTER WASHINGTON DC

 

 

 

Washington D.C., 1 - 4 April 2024

Schedule

Create your personal agenda –check the favourite icon

Apr 110:00
Conference pass

GLOBAL HEALTH mABs [M2] Public-Private collaboration for accessible infectious disease mAbs in LMICs

GLOBAL HEALTH mABs Workshop

Public-Private collaboration for accessible infectious disease mAbs in LMICs

There are significant gaps in monoclonal antibodies (mAbs) access and availability in low- and middle-income countries (LMICs). The highest burden populations for a growing number of licensed mAbs are not benefiting from this class of innovations. Prophylactic, long acting mAbs offer a viable alternative and complementary approach to vaccines in protecting against infections of critical importance in LMICs, but the impact of this established modality may not be realized. Viable business models, commercial incentives and pathways to afford access are currently not in place. Public-Private collaboration will likely be needed to bridge this gap.

Co-organized by: IAVI, Medicines Patent Pool (MPP), Unitaid and Wellcome

Goal of session: To foster mAb developer engagement to understand the barriers and define the incentives and enablers that would facilitate affordable access to mAbs in LMICs.

Target audience: Participants in the World Vaccine Congress, in particular industry stakeholders working in the mAbs field and broader stakeholders with expertise or interest in various aspects related to the development, manufacturing, supply, regulation, and procurement of monoclonal antibodies.

10:00 Introduction

Shelly Malhotra, Executive Director, Global Access, IAVI

10:20 Panel: Challenges and opportunities: What are the barriers and unique considerations for mAbs accessibility/availability in LMICs? What advancements have recently been achieved and how can they be further leveraged for infectious disease mAbs?

Moderator: Carmen Pérez Casas, Strategy Senior Lead/PPPR Head, Unitaid

11:20 Panel: Industry perspectives on a path towards access and the role of global health stakeholders

Moderator: Esteban Burrone, MPP

12:20 Wrap up/Closing remarks

Pete Gardner, Wellcome

Moderator: Anne-Isabelle Cameron, Strategy Technical Officer, UNITAID
Moderator: Shelly Malhotra, Executive Director, Global Access, IAVI
Moderator: Esteban Burrone, Head of Strategy, Policy and Market Access, Medicines Patent Pool
Rachel Mitrovich, Director, Global Vaccines Public Policy, Merck
Erin Sparrow, Technical Officer, Vaccine Product and Delivery Research, World Health Organisation
Pete Gardner, Research Lead, Antibodies & Immunity, Wellcome Trust
Room 202B
Apr 110:00
Conference pass

Strep A Vaccine Industry Forum: Catalyzing Industry Investment in Strep A Vaccine R&D

Strep A Vaccine Workshop

Co-organized by: SAVAC

Objectives: Bring together vaccine developers to seek alignment and investment in Strep A vaccine development.

Andrew Steer, Director of Infection, Immunity and Global Health, and Group Leader of the Tropical Diseases Research Group, The Royal Children's Hospital, Melbourne
Don Walkinshaw, Senior Director, Consulting, Shift Health
Anne Mullin, Principal, Shift Health
Room 206
Apr 110:00
Conference pass

Biodefense & Preparedness [F1]

Biodefense & Preparedness Workshop

What is the progress on new technologies in medical product development?

How our governments are incentivizing (portfolio approach), especially with biotech? What International collaborations are being facilitated?

Moderator: Matthew Hepburn, Chief Medical Officer, JPEO-CBRND
Neil Cherian, Senior Biosecurity and R&D Program Manager, C.E.P.I.
Mike Stebbins, Vice President, Medical CBRN Defense Consortium (MCDC)
Jane True, VP, mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer
C. Malcolm Little, Principal, Arlington Capital Partners
Carmel Devlin, VP Global Regulatory Sciences Vaccines, Pfizer
Rajinder Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers Network
Stephanie Wisner, Chief Business Officer, Centivax
Andrew Kilianski, Senior Director, Emerging Infectious Diseases, International AIDS Vaccine Initiative
Zeshan Muhammedi, MBX Capital
Umesh Shaligram, Executive Director and Head of R&D, Serum Institute of India Ltd
Joël Denis, Director General, Centre for Vaccine and Therapeutic Readiness, Public Health Agency Canada
Joe Fitchett, Co Director of the Delivery Unit, Institut Pasteur de Dakar
Peter Marks, Director, Center For Biologics Evaluation And Research (CBER), U.S. Food and Drug Administration
Bassam Hallis, Deputy Director, Research and Evaluation, UK Health Security Agency
Room 201
Apr 110:00
Conference pass

Vaccine Technology [M1]

Vaccine Technology Workshop

Cutting-edge technologies shaping the future of vaccine development.

10:00 Workshop Leader Opening RemarksDr Wolfgang Leitner, Chief, Innate Immunity Section, NIH

10:10 Innovating Vaccine Development: The Role of VaxArray in SolaVAX, a novel photochemical inactivation vaccine platformDr. Izabela Ragan DVM, Director of Research and Development, Solaris Vaccines

10:30 Revolutionizing mRNA Production: the paradigm-breaking Nfinty™ continuous RNA systemPatrick Thiaville, Chief Technologies Officer, Nucleic Acids, Exothera

10:45 A Novel Intranasal Adjuvant Show to be Safe and Immunogenic in HumansDr Chad Costley, CEO & President, Blue Willow Biologics

11:00 Use of adjuvants to enhance mucosal immunity after vaccinationDr Lisa Morici, Professor, Tulane University School of Medicine

11:15MF59 Adjuvant Mimic: yeast derived squalene and alternative sourcesChase Kempinski, CEO, Enepret

11:30 Alternative uses for adjuvants & cross-over immunotherapy technologies Dr Jay Evans, Chief Scientific and Strategy Officer, Inimmune & Director of the Center for Translational Medicine at the University of Montana

12:00 Emerging discovery tools and technologies David Dowling, Scientist, Division of Infectious Diseases, Instructor in Pediatrics, Harvard Medical School, Boston Children's Hospital, Professor, Harvard Medical SchoolDr Wolfgang Leitner, Chief, Innate Immunity Section, NIHDr Aaron Esser-Kahn, Professor of Molecular Engineering, University of Chicago

Room 202A
Apr 110:00
Conference pass

ANTIMICROBIAL RESISTANCE - Role of vaccines, mABs, phages and antibiotics [F2]

AMR Workshop

A holistic approach will be integral to tackling the AMR pandemic – how is industry ensuring the development of new tools & which interventions are best suited to our priority pathogens?

10:00 Chair opening remarksDr Anna Jacobs, Biologist, Antimicrobials Division, BARDA

10:10 Accelerating the Development of Novel Tools against AMRDr Richard Alm, Chief Scientist, CARB-X

10:40 The application of phages to treat bacterial infectionsDr Steven Theriault, CEO & CSO, Cytophage

11:10 The role of diagnostics in AMRClaire Wingfield, Director, Partnerships and Advocacy, FIND

11:35 The Significance of Robust Health and Economic Data in Tackling Antimicrobial ResistanceLatifat Okara, Principal, Health Policy and Insights, The Economist Impact

12:00-1:00 Panel: What is our AMR strategy: ESKAPE and Priority Pathogens?

  • Which pathogens are more appropriate for vaccine vs mABs development?
  • Challenges of ESKAPE pathogens and innovative approaches.
  • Pre-emptive therapies for patients with colonization of pathogens

Moderator: Dr Kimberly Taylor, Senior Scientific Officer, Biodefense Vaccines, NIHDr Tim Cooke, CEO, OmnioseDr Bret Sellman, Executive Director, Vaccine and Immune Therapies and Head of Bacteriology and Vaccines Discovery, AstrazenecaDr Francesca Micoli, Director GVGH Innovation Academy and Senior Project Leader, GSK Vaccine Institute for Global Health

1:00 - 2:00 Lunch Break

2:00 Combination vaccines to combat AMRDr William Hausdorff, Public Health Value Proposition Lead, PATH

2:30 Shigella and ETEC vaccinesDr Chad Porter, Department Head Translational and ClinicalResearch Defense Infectious Diseases Directorate, Naval Medical Research Center

3:00 Serotype Independent Pneumococcal VaccineDr Tim Hirst, CEO, GPN Vaccines

3:30 Developing Pseudomonas and Klebsiella vaccines using a reverse vaccinology approachDr Rebecca Ingram, Senior Lecturer, Queens University Belfast

3:45 Update on C. diff vaccine developmentDr Erik Lamberth, Senior Director, Vaccine Clinical Research and Development, Pfizer

4:00-5:00 Panel: Defining the value of vaccines against AMR

  • Understanding the role of vaccines as a tool to reduce antimicrobial resistance.
  • Measuring the economic and social value
  • The importance of a One Health approach to tackle AMR
  • The role of behavioural science to improve vaccine uptake and combat vaccine hesitancy.

Moderator: Dr Jomana Musmar, Executive Director, PACCARBDr Jessica Pickett, Director, US Vaccines Health Economics and Outcomes Research, GSKDr Fadi Makki, Partner and Director, BCGDr John Jernigan, Chief, Epidemiology Research and Innovations Branch Division of Healthcare Quality Promotion, CDCYewande Alimi,One Health Unit Lead,Africa CDC

Room 207B
Apr 110:00
Conference pass

RNA - From vaccines to therapeutics

RNA Workshop

How are we improving our understanding of RNA technology for next generation vaccines? How will RNA transform therapeutics and cancer treatment?

10:00 Chair opening remarks

10:10 mRNA vaccines of the future: Bridging the Knowledge GapsDr Sudha Chivukula, AVP, Head of Discovery Biology, mRNA Centre of Excellence, Sanofi

10:25 Beyond respiratory vaccines Dr Jacqueline Miller, SVP, Therapeutic Area Head - Infectious Disease Development, Moderna

10:45Individualized mRNA vaccines Ruben Rizzi, Senior Vice President Global Regulatory Affairs, BioNtech

11:00 Accessing vast design space with modular high throughput platform for RNA therapeutics and vaccinesDr Sarit Schwartz, Head of RNA, Business Development Gingko Bioworks

11:15 Analytical challenges in characterization of multivalent mRNA vaccinesDr Gautam Sanyal, Principal Consultant and Founder, Vaccine Analytics, LLC

11:30 RNABL: A Novel RNA Delivery Platform for Therapeutic ApplicationsDr Micheal Breen, Scientist, Tiba Biotech

11:45 From a preventive vaccine to a therapeutic vaccineDr Jason Zhang, CEO and Co-Founder, ZipCode Bio

12:00 – 1:00 Panel: Beyond prophylactic vaccines: the future of RNA therapeutics

  • What is the potential for RNA use in therapeutics?
  • Cancer, immunotherapy, gene editing etc.
  • What gaps remain to successfully utilize the potential of RNA beyond vaccines?

Moderator: Anna Rose Welch, Editorial and Community Director, Advancing RNA, Life Science Connect Dr Gilles Besin, CSO, Orbital Therapeutics Dr Gopi Shanker, CSO, Beam Therapeutics Dr Andrew Geall, Chief Development Officer, Replicate BioscienceDr Kate Zhang, Chief Scientific Officer, Hopewell Therapeutics

Room 207B
Apr 114:00
Conference pass

Panel: Adult Vaccination: New Vaccines, New Opportunities to Protect Public Health

Adult Immunization Workshop

This session explores solutions that can reshape adult vaccination through policy and system level change (e.g., closing coverage gaps, timeliness of coverage, data systems, equity considerations, alternative administration sites), provider level (e.g., simplification and standardization of recommendations, system prompts), and consumer level (e.g., healthy aging, empowerment and education).

Room 206
Apr 114:00
Conference pass

Vaccine Delivery [A1]

Vaccine Delivery Workshop

Advanced vaccine delivery methods: novel routes and technologies to optimize administration, efficacy, and accessibility.

2:00 Workshop Leader Opening Remarks:David Hoey, President & CEO, Vaxxas

2:10 Microneedle Patches for Measles-Rubella Vaccine Delivery: Gamechangers for Measles and Rubella Elimination:Dr Stephen Crooke, Vaccine Immunology Lead, Viral Vaccine Preventable Diseases, Center for Disease Control and Prevention

2:30 Redefining Access: Prefilled Injectables for Safe and Efficient Vaccinations.:Dr Edward Kelley, Chief Global Health Officer, Apiject

3:00 RNA & MAP - Combining Breakthrough Innovations:Dr Markus Winterberg, Head of Analytical Development, Microbiology, and Quality Control, LTS Lohmann

3:15 Formulate the future: cutting-edge technologies for manufacturing of sustainable components of vaccine delivery systems:Dr Dennis Christensen, Global Head of R&D, Adjuvant Systems, CRODA

3:30 CeraMAPs(tm), the next generation Micro-needle Array Patches:Mike G.W. de Leeuw, CEO, Mylife Technologies

3:45 Improving the performance of vaccines with precision-delivery technologies:Nathalie Landry, CSO PharmaJet

4:15 Consumer Preference for High-Density Microarray Patch to Enable Skin Delivery of Vaccines:Dr Rochelle Chaiken, Chief Medical Officer, Vaxxas

4:30 HalDisc®: A Fast and Reliable Novel Device for VaccinationMariacristina Castelli, Chief Clinical and Regulatory Affairs Officer, Hisamitsu

Room 202A
Apr 114:00
Conference pass

Beyond Efficacy Workshop: Innovating vaccine development and implementation for impact

Beyond Efficacy Workshop

14:00-17:00 Beyond Efficacy: Innovating vaccine development and implementation for impact

Vaccine efficacy is only one determinant of vaccine impact. This workshop will explore innovations throughout the development of a novel vaccine which may ensure better access and equity.Whichever the theme each year, it will challenge our thinking, our dogmas and perhaps reveal new horizons. It honoursDr Mike Watson, a true vaccinologist and original thinker.

2pm Workshop leader opening remarks:Dr Angus Thomson,Principal,Irimi Company

2:20pm Presentation 1:Program implementation – Electronic Immunization Records are foundational for equitable vaccination (and PHC)

EIRs can reduce HCW workload,track the un- and under-vaccinated and be leveraged in many ways to build vaccine demand and uptake. They can facilitate a switch from input-based financing to results-based financing, a transformational shift which can drive vaccine uptake and may be a scaffold for many other PHC services.

Rustam Nabiev, Director,Shifo Foundation

2:50pm Presentation 2:Outracing the Outbreak: CEPI’s Mission to Develop Vaccines in 100 Days

To meet its vision of developing a pandemic vaccine within 100 days, CEPI identified a number of transformational innovations in technologies, processes and partnerships that will be required. What are these necessary shifts in what we do and in how we think and act? And how can they inform the development and delivery of routine vaccines as well?

Dr Rebecca Farkas, Director of Dept of R&D Innovations,CEPI

3:20pm Presentation 3:How do we make sure that the vaccines we develop are what countries want? Recent new vaccine technologies such as mRNA, peptides or VLPs allow for rapid, flexible and scalable development and production of new vaccine candidates. But these innovations mean little if they aren’t translated into vaccines that used. How can we mapthe potential public health, economic and societal value and the realities of vaccination programs when selecting candidate vaccines.

Dr William Hausdorff,Public Health Value Proposition Lead,PATH

3:50pm Panel Discussion:

Moderator: Dr Angus Thomson,Irimi Company

(Hamilton Bennett, Moderna)

Rustum Nabiev,Shifo Foundation

William Hausdorff, PATH

Rebecca Farkas, CEPI

Room 207A
Apr 114:00
Conference pass

Global Health & NTDs [A2]

Global Health Workshop (NTDs)

Identifying innovative and collaborative solutions throughout the development pathway to advance NTD vaccine candidates beyond historical roadblocks.

2:00 Workshop Leader Opening Remarks

Dr Simona Rondini, Head Bacterial Projects and Senior Project Leader, GSK Vaccines Institute for Global Health

2:20 Panel: Optimizing pre-clinical frameworks to maximize successful transition of NTD vaccines into the critical path

Moderator: Dr Maria Elena Bottazzi, Co-Director of Texas Children’s Hospital for Vaccine Development, Baylor College of Medicine

Dr Phillip Felgner, Director, UCI Vaccine Research & Development Center & Protein Microarray Laboratory and Training Facility, University of California IrvineDr Simona Rondini, Head Bacterial Projects and Senior Project Leader, GSK Vaccines Institute for Global Health

Dr Jeffrey Bethony, Professor & Vice Chair for Translational Research, Department of Microbiology, Immunology & Tropical Medicine, The George Washington University

Dr Jay Evans, Chief Scientific and Strategy Officer, Inimmune & Director of the Center for Translational Medicine at the University of Montana

3:20 Panel: Navigating the Critical Path: Advancing NTD Vaccines Beyond Phase II

Moderator: Dr Orin Levine, Non-Resident Fellow, Center for Global Development

Dr David Diemert, Professor & Clinical Director, GW Vaccine Research Unit, The George Washington University

Amy Finan, CEO, Sabin Vaccine Institute

Dr Milagritos Tapia, Professor of Pediatrics, University of Maryland

4:15 Transnational & Regional Approaches to Pandemic PreparednessDr Jerome Kim, Director General, IVI

Prof Leo Poon, Chair of Public Health Virology, The University of Hong Kong

Gaurav Pandey, Head of Vaccine Process Development, IVI

Room 202B
Apr 115:45
Conference pass

Panel: Achieving the WHO Cervical Cancer Elimination Goal: Why Partnerships Matter

HPV Workshop

This session will highlight the importance of innovation in driving progress towards the WHO’s elimination targets, and how partnerships between industry and other multi-sectoral partners working towards achieving cervical cancer elimination has helped accelerate progress towards

Room 206

Create your personal agenda –check the favourite icon

Apr 28:30
Conference pass

Chair's Opening Remarks

Keynotes
Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Keynote, Hall D
Apr 28:45
Conference pass

Opening Keynote Address: Female pioneers in developing and implementing lifesaving vaccines

Keynotes
  • How do women in leadership and their leadership styles play positive a role? (and what are the challenges to that and how have you handled it?)
  • How has each of your different leadership roles pushed you in new ways?
  • What drives you and how do you measure your success?
  • What have you witnessed in your career that shows progress towards better inclusion?
Nicole Lurie, Executive Director of Prepardness and Response, CEPI-US
Peggy Hamburg, Co-President, The InterAcademy Partnership & Former US FDA Commissioner, The InterAcademy Partnership
Penny Heaton, Global Therapeutic Area Head, Vaccines, Janssen Pharmaceutical companies of Johnson & Johnson
Keynote, Hall D
Apr 29:45
Conference pass

Keynote panel: What is the end-to-end life cycle of pandemic vaccines – what do we need to do before, during and after?

Keynotes
  • What are the synergistic differences between BARDA and HERA?
  • What did we learnfrom COVID and how do we plan to fix the issues we encountered?
  • How will we manage stockpiles more efficiently and fairly?
  • What kind of regulatory flexibility and framework is in place to support pandemic vaccines?
  • How do we exit out of EUAs to fully approved vaccines rapidly to get the coverage we want?
Karin Bok, Director of Pandemic Preparedness and Emergency Response, Vaccine Research Center, NIAID, NIH
Nicole Lurie, Executive Director of Prepardness and Response, CEPI-US
David Kaslow, Office Director, FDA
Gary Disbrow, Director, BARDA
Michinari Hamaguchi, Director General, AMED SCARDA
Keynote, Hall D
Apr 211:40
Conference pass

Keynote panel: The priority list review – What is our global strategy to priority pathogens and what about the neglected diseases?

Keynotes
  • Which pathogens need more research and which need to be developed by manufacturers?
  • What about the AMR and neglected diseases lists? Where does that fit?
  • Do we have the right strategy to enable us to create the next pandemic vaccine even faster than COVID? Prototype families and platformed based pandemic preparedness models?
  • How do we interpret the lists for vaccine development?
Keynote, Hall D
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 1: Competitive Enrolment: Has this strategy run its course?

Interactive Roundtables
Room 206
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 10: Challenges in manufacturing vaccine antigens and mRNA

Interactive Roundtables
Room 201
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 11: Next-Generation mRNA Developments: Anticipated Tools and Trends in the Next Five Years

Interactive Roundtables
Room 207A
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 12: Practical Challenges for Universal Vaccines

Interactive Roundtables
Room 203AB
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 13: Navigating Government Funding for Biotechs and Biopharmas

Interactive Roundtables
Room 204C
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 14: Cracking the Code: Unraveling ePro Challenges in Vaccine Trials

Interactive Roundtables
Room 209A
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 15: Title TBC

Interactive Roundtables

Reserved for Premas Biotech

Room 204A
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 2: Why vaccine demand is the greatest challenge we are going to face over the next ten years, and what are we going to do about it?

Interactive Roundtables

In many developing countries, social media usage is growing at a rate of 50% per year and disinformation is increasing. In some African countries, a majority of adults did not have sufficient trust to accept a Covid vaccination. The response from governments to misinformation and trust deficits often uses 19th century rather than 21st century technology.

This roundtable discussion is focused on sharing ideas to help change that, covering topics such as:

Transforming data-use in demand work through rapid surveys and pulse checks Achieving a step-change in the use of social media to combat misinformation

Utilizing 21st century approaches to understand and respond to vaccine hesitancy

Strengthening government capacity to rapidly and proactively respond to rumors and misinformation

Lessons learned from the private sector in approaching demand and communications

Room 209B
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 3: Sustainable speed in vaccine development

Interactive Roundtables
Room 208AB
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 4: Unique considerations for conducting pediatric vaccine trials

Interactive Roundtables
Room 204B
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 5: Precise Viral Quantification with Laser Force Cytology™ - Rapid Potency & Real-time PAT for Improved Process and Manufacturing Quality Control

Interactive Roundtables

In this roundtable scientific experts will discuss the importance of accurate and precise viral titers both as analytical assays and real-time process analytical technology (PAT). From raw material characterization to the measurement of precise infectious titer during process development, manufacturing, and QC the measurement of viral infectivity is a critical parameter for consistent quality assurance throughout vaccine development and production workflows.

Room 202A
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 6: Immunogenicity Assays: Selection and Tradeoffs

Interactive Roundtables
Room 202B
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 7: Operationalizing remote and multi-site PIs for Vaccine trials

Interactive Roundtables
Room 207B
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 8: Public Health Priorities: The emerging threat of Zika and Chikungunya

Interactive Roundtables
Room 209C
Apr 211:40
Conference pass

[ROTATION 1] Roundtable 9: How sponsors can work with sites to improve diverse patient representation

Interactive Roundtables
Room 201
Apr 212:25
Conference pass

Fireside chat: Prevention of RSV in the pediatric population

Keynotes
  • Use of mABs and vaccines in infants and children – which should be use and when?
  • Future of mABs in global accessibility and cost-effectiveness
  • Continued RSV vaccine development opportunities – where are the largest needs?
Michelle Roberts, Global Medical Franchise Head , RSV, Vaccines, Sanofi
Alejandra Gurtman, Sr VP, Vaccines Clinical R&D, Pfizer
Keynote, Hall D
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 1: Competitive Enrolment: Has this strategy run its course?

Interactive Roundtables
Room 206
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 10: Challenges in manufacturing vaccine antigens and mRNA

Interactive Roundtables
Room 201
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 11: Next-Generation mRNA Developments: Anticipated Tools and Trends in the Next Five Years

Interactive Roundtables
Room 207A
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 12: Practical Challenges for Universal Vaccines

Interactive Roundtables
Room 203AB
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 13: Navigating Government Funding for Biotechs and Biopharmas

Interactive Roundtables
Room 204C
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 14: Cracking the Code: Unraveling ePro Challenges in Vaccine Trials

Interactive Roundtables
Room 209A
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 15: Title TBC

Interactive Roundtables

Reserved for Premas Biotech

Room 204A
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 2: Why vaccine demand is the greatest challenge we are going to face over the next ten years, and what are we going to do about it?

Interactive Roundtables

In many developing countries, social media usage is growing at a rate of 50% per year and disinformation is increasing. In some African countries, a majority of adults did not have sufficient trust to accept a Covid vaccination. The response from governments to misinformation and trust deficits often uses 19th century rather than 21st century technology.

This roundtable discussion is focused on sharing ideas to help change that, covering topics such as:

Transforming data-use in demand work through rapid surveys and pulse checks Achieving a step-change in the use of social media to combat misinformation

Utilizing 21st century approaches to understand and respond to vaccine hesitancy

Strengthening government capacity to rapidly and proactively respond to rumors and misinformation

Lessons learned from the private sector in approaching demand and communications

Room 209B
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 3: Sustainable speed in vaccine development

Interactive Roundtables
Room 208AB
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 4: Unique considerations for conducting pediatric vaccine trials

Interactive Roundtables
Room 204B
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 5: Precise Viral Quantification with Laser Force Cytology™ - Rapid Potency & Real-time PAT for Improved Process and Manufacturing Quality Control

Interactive Roundtables

In this roundtable scientific experts will discuss the importance of accurate and precise viral titers both as analytical assays and real-time process analytical technology (PAT). From raw material characterization to the measurement of precise infectious titer during process development, manufacturing, and QC the measurement of viral infectivity is a critical parameter for consistent quality assurance throughout vaccine development and production workflows.

Room 202A
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 6: Immunogenicity Assays: Selection and Tradeoffs

Interactive Roundtables
Room 202B
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 7: Operationalizing remote and multi-site PIs for Vaccine trials

Interactive Roundtables
Room 207B
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 8: Public Health Priorities: The emerging threat of Zika and Chikungunya

Interactive Roundtables
Room 209C
Apr 212:30
Conference pass

[ROTATION 2] Roundtable 9: How sponsors can work with sites to improve diverse patient representation

Interactive Roundtables
Room 201
Apr 213:00
Conference pass

Networking Break

Exhibition Hall

Join us in the exhibition hall (level 3) for:

1:10 – 2:30 1-2-1 Partnering

1:30 – 2:20 Start-up pitches

2:00 – 2:30 Poster Presentations

Exhibition Hall D, Level 2
Apr 213:30
Conference pass

Start-up Pitch: Re-inventing vaccines with PIV5: a safe and scalable intranasal viral vector

Start-up Pitches
Keynote, Hall D
Apr 213:35
Conference pass

Start-up Pitch: Baiya Phytopharm: We Grow The Plants of Life

Start-up Pitches
Keynote, Hall D
Apr 213:40
Conference pass

Start-up Pitch: Leveraging the innovative NDV-vector platform to develop vaccines targeting pathogens with substantial unmet need

Start-up Pitches
Keynote, Hall D
Apr 213:45
Conference pass

Start-up Pitch: Next-generation Platforms for innovative bacterial vaccines

Start-up Pitches
Keynote, Hall D
Apr 213:50
Conference pass

Start-up Pitch: CrisBio®: A novel, natural and scalable protein expression system.

Start-up Pitches
Keynote, Hall D
Apr 213:55
Conference pass

Start-up Pitch: Iaso Therapeutics, A new conjugate vaccine company

Start-up Pitches
Keynote, Hall D
Apr 214:00
Conference pass

Start-up Pitch: Advancing Rapid Immunity Surveillance

Start-up Pitches
Keynote, Hall D
Apr 214:30
Conference pass

Keynote from the CDC: Protecting Health & Preparing for the Future

Keynotes
Mandy Cohen, Director, CDC
Keynote, Hall D
Apr 214:50
Conference pass

Keynote panel: Implementing vaccine manufacturing in Africa: Transitioning from manufacturing capability to long term sustainability

Keynotes
  • Now we’ve built local manufacturing – is it sustainable?
  • Are these decentralized manufacturing hubs working and is the infrastructure also in place to support it?
  • How will African producers start matching the multinational manufacturers in production? The role of international and national collaborations
  • The need for regulatory strengthening and infrastructure
  • How do we ensure vaccine acceptability and uptake of vaccines manufactured from Africa?
Abebe Genetu Bayih, Ag. PAVM Coordinator, Africa CDC
Analia Acebal, Vaccine Manufacturing Lead Consultant, CEPI
Petro Terblanche, Chief Executive Officer, Afrigen Biologics (Pty) Ltd
Keynote, Hall D
Apr 215:40
Conference pass

Keynote panel: Gaps in Adult Immunization – the next frontier: What is our strategy for better disease prevention and control?

Keynotes
  • As the adult vaccination choices get more crowded, what are our implementation strategies and key challenges?
  • How do we navigate current ACIP recommendations for best vaccine uptake of RSV?
  • How will that impact other new adult vaccines reaching the market?
  • Co-administrating vaccines vs combination vaccines – how do we evaluate these?
Moderator: Litjen Tan, Chief Strategy Officer, Immunization Action Coalition
David Kaslow, Office Director, FDA
Annaliesa Anderson, SVP and Head, Vaccine R&D, Pfizer
Keynote, Hall D
Apr 216:30
Conference pass

Keynote panel: Defining and developing broadly protective vaccines

Keynotes
  • How do we develop and evaluate the effectiveness second/next generation vaccines
  • Lesson learned in universal flu vaccine efforts
  • What developments have been made towards broadly protective vaccines?
Dan Barouch, Professor Of Medicine, Harvard Medical School
Peter Palese, Professor And Chair Microbiology, Mount Sinai School of Medicine
Peter Marks, Director, Center For Biologics Evaluation And Research (CBER), U.S. Food and Drug Administration
Keynote, Hall D
Apr 217:20
Conference pass

Pre-award Networking Drinks

Networking Drinks

Sponsored by Tekton Research

Ballroom Foyer, LEVEL 3
Apr 217:20
Conference pass

Chair’s Closing Remarks and Close of Congress Day 1

Keynotes
Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Keynote, Hall D
Apr 219:00
Conference pass

Gala Dinner & 16th Annual ViE Awards Ceremony

Keynotes

Only those who have paid for the ViE admission can attend.

Ball Room, Level 3

Create your personal agenda –check the favourite icon

Apr 39:00
Conference pass

Chair's Opening Remarks

COVID & BEYOND
Jerald Sadoff, Chief Medical Officer, Centivax
Room 207A
Apr 39:00
Conference pass
Apr 39:00
Conference pass

Chair's opening remarks

Cancer Immunotherapy
Room 206
Apr 39:00
Conference pass

Chair's opening remarks

Emerging & Re-Emerging Diseases
Marion Gruber, Vice President of Public Health and Regulatory Affairs, IAVI
Room 202B
Apr 39:00
Conference pass
Apr 39:00
Conference pass

Chair's Opening Remarks

Bioprocessing & Manufacturing
Irina Ramos, Director, Bioprocess Technologies & Engineering, AstraZeneca
Room 209AB
Apr 39:00
Conference pass

Chair's Opening Remarks

Veterinary Vaccines and One Health
Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Room 204AB
Apr 39:00
Conference pass
Apr 39:00
Conference pass
Apr 39:00
Conference pass

Chair's Opening Remarks

Vaccine Supply & Logistics
Room 209C
Apr 39:05
Conference pass

Panel: Vaccine manufacturing insights from Asia: Strengthening vaccine production capacity and capabilities

Bioprocessing & Manufacturing
  • Lessons from the rapid scale up of production capacity to meet pandemic vaccine demand and how we maintain these capabilities post-pandemic.
  • How do we stimulate global collaboration between Asia and the rest of the world?
  • Strengthening of regulatory systems and alignment between countries
  • What is Asia’s appetite in introducing new technologies into their manufacturing capabilities?
Room 209AB
Apr 39:10
Conference pass

Panel: The future of COVID-19 vaccinations. Should we be developing broadly protective antigens or combinational vaccines?

COVID & BEYOND
  • The future of COVID-19 vaccinations: combined annual shots for a seasonal disease with flu and RSV?
  • How do we compare the effectiveness of combined respiratory vaccines?
Piyali Mukherjee, Vice President Head Medical Affairs, gsk
Joshua Nealon, Medical lead: Pre-licensure Flu and COVID-19 vaccines, Sanofi Vaccines
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Room 207A
Apr 39:10
Conference pass

Monoclonal antibodies for prophylaxis of infectious disease

Immune Profiling
Room 207B
Apr 39:10
Conference pass

Panel: Exploring the future prospects of cancer vaccines

Cancer Immunotherapy
  • Exploring the role and prospects of (neo)adjuvant cancer vaccines in the therapeutic landscape: adjuvant versus neoadjuvant, prevention of reoccurrence vs truly therapeutic, value in metastatic disease
  • Indications & immune characteristics: hot versus cold tumors & TME
  • Is there potential for off-the-shelf vaccines? What might this strategy look like?
Room 206
Apr 39:10
Conference pass

What is the burden and uptake for RSV vaccines?

Influenza & Respiratory
  • Updates, epidemiology and vaccine fatigue
  • What is the role of mAbs and vaccines for RSV protection?
  • How to we ensure better global health accessibility of RSV vaccines?
Room 202A
Apr 39:10
Conference pass

The future of global health: How to Advance detection and response capacity for Emerging & Re-emerging Pathogens in Africa & LMICs

Emerging & Re-Emerging Diseases
  • Public health preparedness
  • Rapid pathogen identification and proactive surveillance systems
Room 202B
Apr 39:10
Conference pass

Evolving Vaccine Trials: The Power of a Comprehensive Hybrid Strategy for Improved Access

Clinical Trials
Room 208AB
Apr 39:10
Conference pass

Emerging & re-emerging zoonotic diseases: what are our priority pathogens for spill over & pandemic risk?

Veterinary Vaccines and One Health
Room 204AB
Apr 39:10
Conference pass

Panel: Middle East – how did their infrastructure hold during COVID? Case studies and experiences

Vaccine Partnerships
Moderator: Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
Rashad Massoud, Visiting Lecturer, Harvard T.H. Chan School of Public Health
Mashal Almutairi, Chief Executive Officer, Scientific Affairs and Vaccines Development and Manufacturing, Vaccine Industrial Company
Room 201
Apr 39:10
Conference pass

Studies to investigate the non-specific effects of vaccines and their importance in HICs and LMICs

Vaccine Safety
Room 204C
Apr 39:10
Conference pass

An agile approach to PBMC collection in Vaccine Trials – Title TBC

Vaccine Supply & Logistics
Room 209C
Apr 39:10
Conference pass

The evolving role of the ACIP

Market Access
  • How have ACIP processes changed in recent years?
  • How does the ACIP teamwork across the US government divisions and the medical community within the recommendation process?
  • Tackling under-resourcing in advisory committees
  • How to create efficiencies in systems to help ensure rapid and seamless implementation of recommendations
  • View on health economics assessments
Room 203AB
Apr 39:40
Conference pass

Systems Immunology - Title TBC

Immune Profiling
Room 207B
Apr 39:40
Conference pass

Nirsevimab, a monoclonal antibody for protection of all infants from RSV

Influenza & Respiratory
Room 202A
Apr 39:40
Conference pass

Antibody persistence of a single-dose live-attenuated chikungunya virus vaccine (VLA1553) in adults

Emerging & Re-Emerging Diseases
Room 202B
Apr 39:40
Conference pass

Unlocking the Potential: Operationalizing Therapeutic Vaccine Trials for Enhanced Patient Outcomes

Clinical Trials
Room 208AB
Apr 39:40
Conference pass

Understanding biological mechanisms of AESIs and enhancing capacity for vaccine safety studies in LMICs

Vaccine Safety
Room 204C
Apr 39:40
Conference pass

The Role of Coordination and Communication in maintaining high quality sample processing of PBMCs

Vaccine Supply & Logistics
Room 209C
Apr 39:55
Conference pass

VLP Vaccine and mRNA Vaccine Development & Manufacturing Platform

Bioprocessing & Manufacturing
Room 209AB
Apr 39:55
Conference pass

Re-Shaping the Clinical Research Supply Chain in sub-Saharan Africa

Vaccine Supply & Logistics
Room 209C
Apr 310:10
Conference pass

Safety and Immunogenicity of the Novavax XBB.1.5 SARS-CoV-2 Vaccine in Previously mRNA Vaccinated Participants

COVID & BEYOND
Room 207A
Apr 310:10
Conference pass

Harnessing translational modelling approaches to accelerate next-generation mRNA vaccine development

Immune Profiling
Room 207B
Apr 310:10
Conference pass
Apr 310:10
Conference pass

Pandemic Preparedness; from proof of concept to clinic

Influenza & Respiratory
Room 202A
Apr 310:10
Conference pass

Updates on Bavarian Nordic's Chikungunya Vaccine Candidate

Emerging & Re-Emerging Diseases
Hristu Gache, Global Lead, Vaccines, Bavarian Nordic
Room 202B
Apr 310:10
Conference pass

Preclinical Services - From In Vivo Animal Studies to In Vitro Assay Development and Testing

Clinical Trials
Room 208AB
Apr 310:10
Conference pass

Formulation Development of Thermostable Lyophilized and Liquid Vesicular Stomatitis Virus-based Vaccine

Bioprocessing & Manufacturing
Room 209AB
Apr 310:10
Conference pass

Developing novel partnership model for vaccines in EID

Vaccine Partnerships
  • - Prioritizing pathogens where there is no clear market
Swati Gupta, VP, Head of Emerging Infectious Diseases and Epidemiology, International AIDS Vaccine Initiative
Room 201
Apr 310:10
Conference pass

Leveraging the rollout of COVID-19 vaccines to strengthen pharmacovigilance systems in Africa

Vaccine Safety
Room 204C
Apr 310:10
Conference pass

DNA-encoded mAbs: addressing barriers for improved access

Vaccine Supply & Logistics
Room 209C
Apr 310:10
Conference pass

Pathways to licensure for emerging disease vaccines – Marburg & Sudan Ebola

Market Access
Room 203AB
Apr 310:25
Conference pass

Distinct Differences in IgG4 switch and Fc effector functions between mRNA and Novavax protein-based COVID Vaccination

COVID & BEYOND
Raj Kalkeri, Translational Medicine Lead, Novavax
Room 207A
Apr 310:25
Conference pass

Advances in the technologies used to study human B-cell repertoires

Immune Profiling
Room 207B
Apr 310:25
Conference pass

Liquid biopsies & ctDNA in treatment response & MRD monitoring

Cancer Immunotherapy
Maria Karasarides, Former Vice President, Head of Early Assets and Biomarkers, Bristol Myers Squibb
Room 206
Apr 310:25
Conference pass

Development of an inactivated EV D68 vaccine using Vero cell platform technology

Emerging & Re-Emerging Diseases
Dinja Oosterhoff, VP R&D, Intravacc
Room 202B
Apr 311:40
Conference pass

Preparation of the CEPI Centralized Laboratory Network for Future Outbreaks

COVID & BEYOND
Room 207A
Apr 311:40
Conference pass

Development and Validation of Luminex xMAP for Pneumococcal Multi-valent Conjugate Vaccines.

Immune Profiling
Room 207B
Apr 311:40
Conference pass

Current development of an mRNA vaccine for RSV

Influenza & Respiratory
Room 202A
Apr 311:40
Conference pass

The reality of the changing disease landscape and the role that new AI technology can play in getting ahead

Emerging & Re-Emerging Diseases
  • Navigating the greater frequency, severity of diseases, and lack of predictability in infectious diseases
Room 202B
Apr 311:40
Conference pass

Overcoming challenges with maternal vaccine trials

Clinical Trials
  • Delivery of vaccines prior to, or during pregnancy provides benefits to the pregnant women, developing fetus and the newborn infant
  • While vaccinations during pregnancy provide benefits, hesitancy continues from both the pregnant women and partner, which also impacts enrollment for maternal trials
  • Maternal vaccine studies have many unique challenges with considering the health of both the pregnant women and the baby
Room 208AB
Apr 311:40
Conference pass

Navigating Vaccine Processing, Formulation and Stability with Consistent, High-Quality Recombinant Albumin

Bioprocessing & Manufacturing
Room 209AB
Apr 311:40
Conference pass

A vaccine for bees: targeting pollinator health for future food security

Veterinary Vaccines and One Health
Room 204AB
Apr 311:40
Conference pass

Collaborative Symbiosis: Enhancements to CRO & Site Ways of Working

Vaccine Partnerships
Randall Severance, Director Medical Operations, AES Corporation
Tina Morgenstein, Project Director in the Vaccine Therapeutic Unit, PPD, Part of Thermo Fisher Scientific
Room 201
Apr 311:40
Conference pass

V-safe Overview

Vaccine Safety
Room 204C
Apr 311:40
Conference pass

Panel: Partnerships between industry and vaccine implementation programs

Vaccine Supply & Logistics
  • What is needed to design tiered pricing for vaccines?
  • How is current vaccine supply being planned assured, particularly with LMICs?
  • Navigating limited supply of vaccines market availability increases
  • How industry and government are working with NGOs and mechanisms like GAVI to make vaccines more accessible
  • MIC countries and affordability of vaccine supply programs.
Room 209C
Apr 311:40
Conference pass

Medicaid reimbursement in the pharmacy space

Market Access
Room 203AB
Apr 311:55
Conference pass

Characterizing vaccine-induced immune responses with ELISpot and FluoroSpot assays

Immune Profiling
Room 207B
Apr 312:10
Conference pass

Long-term Immunity Induced by a Novel samRNA-based Vaccine Approach to COVID-19 in HIV Negative Populations and People Living with HIV

COVID & BEYOND
Room 207A
Apr 312:10
Conference pass

How can we better leverage the data we have?

Immune Profiling
Room 207B
Apr 312:10
Conference pass

Strategies for Improving in vivo Study Data Rigor and Reproducibility

Cancer Immunotherapy
Room 206
Apr 312:10
Conference pass

RSV for older adults

Influenza & Respiratory
Megan Riley, Director of Scientific For Rsv Adult Vaccine, GSK
Room 202A
Apr 312:10
Conference pass

Persistence of Ebola vaccine elicited immune responses

Emerging & Re-Emerging Diseases
Jennifer Hendriks, Head Biomarkers and Clinical Immunology, Janssen Vaccines & Prevention B.V.
Room 202B
Apr 312:10
Conference pass

Bacterial Vaccines: Their Role Against Antimicrobial Resistance and the Challenges for Clinical Development

Clinical Trials
  • Recent changes in antimicrobial resistance
  • The potential of vaccines to prevent antibiotic resistance
  • Identifying the priority pathogens for new antibiotic research and development
  • Clinical trial challenges in developing vaccines against bacteria
  • Regulatory and approval pathways – success through collaboration
Room 208AB
Apr 312:10
Conference pass

Advancements in mRNA Capping Technology for Vaccine Development

Bioprocessing & Manufacturing
Room 209AB
Apr 312:10
Conference pass

Next Generation DNA vaccines for ‘One Health’ – Title TBC

Veterinary Vaccines and One Health
Room 204AB
Apr 312:10
Conference pass

Panel: The collaborative role of developing country vaccine manufacturers in global immunization and pandemic preparedness

Vaccine Partnerships
Moderator: Rajinder Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers Network
Mauricio Zuma Medeiros, Chief Executive Officer, Bio-Manguinhos, Fiocruz
Sunil Gairola, Executive Director, Serum Institute of India Ltd
Room 201
Apr 312:10
Conference pass

Brighton Collaboration Case Definitions: Digital Transformation for Pandemic Preparedness

Vaccine Safety
Room 204C
Apr 312:10
Conference pass

What’s next after the Inflation Reduction Act?

Market Access
  • What gaps remain? Low-income adults’ barriers to vaccination
  • Changes in coverage - eliminating cost sharing for adult vaccines covered under part D and improving access to adult vaccines in Medicaid and CHIP
  • Who is not funded? (Uninsured adults)
  • Supporting vaccine providers
  • Access and equity barriers for adult vaccines
Room 203AB
Apr 312:25
Conference pass

Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancers

Cancer Immunotherapy
Room 206
Apr 312:25
Conference pass

Prevention of Infant RSV Illness with a bivalent RSVPreF Vaccine in Pregnancy

Influenza & Respiratory
Room 202A
Apr 312:25
Conference pass

Panel: Vaccine development and efforts towards eradicating Chikungunya

Emerging & Re-Emerging Diseases
Moderator: Sushant Sahastrabuddhe, Deputy Director General, International Vaccine Institute
Juan Carlos Jaramillo, Chief Medical Officer, Valneva
Room 202B
Apr 312:40
Conference pass

Strategy for Effective Screening and Identification of Monoclonal Antibodies Against Omicron Kraken Subvariant and other SARS-CoV-2 Variants of Concern

COVID & BEYOND
Room 207A
Apr 312:40
Conference pass

Leveraging different Fc-biology across Infections – Title TBC

Immune Profiling
Galit Alter, VP of Immunology Research, Moderna
Room 207B
Apr 312:40
Conference pass

Impact of mRNA technology towards streamlining vaccine candidate and TCR screening

Cancer Immunotherapy
Room 206
Apr 312:40
Conference pass

Frontiers of vaccine development: sustainable speed at scale

Clinical Trials
Room 208AB
Apr 312:40
Conference pass

Evolving vaccine standards to support quality throughout the product lifecycle: from raw materials to drug product

Bioprocessing & Manufacturing
Room 209AB
Apr 312:40
Conference pass

Objective selection of virus strains from sequence data for pandemic preparedness

Veterinary Vaccines and One Health
Room 204AB
Apr 312:40
Conference pass

Attenuation of the Horsepox Vaccine Platform for a Mpox/Smallpox Vaccine (TNX-801)

Vaccine Safety
Room 204C
Apr 312:40
Conference pass

Avoiding key material bottlenecks with improved regulatory strategies – title TBC

Vaccine Supply & Logistics
Room 209C
Apr 312:55
Conference pass

Challenges for the availability of vaccines and drugs against infectious diseases: regulatory perspectives

Vaccine Supply & Logistics
Room 209C
Apr 313:25
Conference pass

Start-up Pitch: Developing synergistic vaccines and therapeutics against infectious disease

Start-up Pitches
Keynote, Hall D
Apr 313:30
Conference pass

Start-up Pitch: Designing Vaccines with Virus Evolution Prediction

Start-up Pitches
Keynote, Hall D
Apr 313:35
Conference pass

Start-up Pitch: Neomatrix: an innovative, fully-synthetic DNA platform for next generation Cancer Vaccines

Start-up Pitches
Keynote, Hall D
Apr 313:40
Conference pass

Start-up Pitch: Designing a Cure: Overcoming Post-viral Illness & Solving Antimicrobial Resistance

Start-up Pitches
Keynote, Hall D
Apr 313:45
Conference pass

Start-up Pitch: Enabling Equitable Access, One API at a Time

Start-up Pitches
Keynote, Hall D
Apr 313:50
Conference pass

Start-up Pitch: Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages

Start-up Pitches
Keynote, Hall D
Apr 313:55
Conference pass

Start-up Pitch: Correlia Biosystems introduces the PIXI microfluidic platform to run ultra-efficient, rapid, and automated ELISA and immunoassays

Start-up Pitches
Keynote, Hall D
Apr 314:00
Conference pass

Start-up Pitch: Turbo: an adjuvant for bacterial polysaccharide vaccines

Start-up Pitches
Keynote, Hall D
Apr 314:25
Conference pass

Clinical development update on OVX836, a T-cell based broad spectrum influenza vaccine

Influenza & Respiratory
Room 202A
Apr 314:40
Conference pass

Innovation in Vaccine and Antimicrobial Drug Development, Lessons from our Statistics, Surveillance and Commercial Experience

COVID & BEYOND
Jaime E Hernandez, Executive Medical Director, Clinical Development, Syneos Health
Room 207A
Apr 314:40
Conference pass

Using high dimensional immune profiling in human disease to interrogate individual responses to therapeutic interventions

Immune Profiling
Room 207B
Apr 314:40
Conference pass

Targeting mKRAS Vaccination to the Lymph Nodes to Promote Anti-tumor Immunity: Preliminary Results from the Phase 1 AMPLIFY-201 Trial

Cancer Immunotherapy
Room 206
Apr 314:40
Conference pass

Update on Novavax influenza and COVID-influenza combination vaccine

Influenza & Respiratory
Room 202A
Apr 314:40
Conference pass

Key Updates on Bavarian Nordic's JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Non-replicating)

Emerging & Re-Emerging Diseases
Peter Costa, US Medical Affairs, Bavarian Nordic
Room 202B
Apr 314:40
Conference pass

A Decade of Advancements: Electronic Tools Revolutionizing Vaccine Clinical Trial Operations

Clinical Trials
Andres Rozo, Executive Director, Vaccine eTools for Clinical Trials, Integra IT
Room 208AB
Apr 314:40
Conference pass

Pfenex Expression Technology®: A Primrose Bio platform to enable production of vaccine antigens

Bioprocessing & Manufacturing
Room 209AB
Apr 314:40
Conference pass

Next generation Rift Valley fever vaccine, RVax-1

Veterinary Vaccines and One Health
Room 204AB
Apr 314:40
Conference pass

Showcase 1: A simple, safe, affordable and scalable intracellular delivery platform for mRNA/DNA vaccines

Vaccine Partnerships
Room 201
Apr 314:40
Conference pass

Assessment of stroke risk following covid-19 bivalent and certain influenza vaccines among US older adults

Vaccine Safety
Room 204C
Apr 314:40
Conference pass

Breaking the Cold-Chain: Room Temperature Storage Vaccines and Biologics

Vaccine Supply & Logistics
Room 209C
Apr 314:40
Conference pass

Post-covid - funding and resource challenges to maintaining sustainable vaccine infrastructure for adults

Market Access
  • What happens to all of the programs funded by covid?
  • Will the systems that were built continue to function
  • Partners and communities on the ground who helped eliminate disparity will no longer exist
Room 203AB
Apr 314:55
Conference pass

A Quadrivalent mRNA immunization elicits potent immune responses against monkeypox viral antigens – a step closer to a broad orthopoxvirus vaccine

Emerging & Re-Emerging Diseases
Room 202B
Apr 314:55
Conference pass

Promoting Inclusivity in Vaccine Trials: Ensuring Representation of Diverse Populations in Middle East and Africa

Clinical Trials
Room 208AB
Apr 314:55
Conference pass

One Health Vaccines for TB in Cattle and Bison

Veterinary Vaccines and One Health
Room 204AB
Apr 314:55
Conference pass

Showcase 2: Why you should conduct your next vaccine trial in Africa

Vaccine Partnerships
Catherine Lund, managing Director, OnQ Research
Room 201
Apr 314:55
Conference pass

Expanding Vaccine Access By Use of Affordable Prefilled Formats

Vaccine Supply & Logistics
Room 209C
Apr 315:10
Conference pass

Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination

COVID & BEYOND
Sean Tucker, CSO, Vaxart
Room 207A
Apr 315:10
Conference pass

Targeting T-cell responses to conserved regions of major viral families to modulate and prevent severe disease

Immune Profiling
Room 207B
Apr 315:10
Conference pass

NOUS-209 genetic vaccine encoding shared neoantigens for treatment and interception of MSI tumors

Cancer Immunotherapy
Room 206
Apr 315:10
Conference pass

New advances in respiratory virus challenge models improving their value for vaccine efficacy testing and host response disease monitoring

Influenza & Respiratory
Andrew Catchpole, CSO, hVIVO
Room 202A
Apr 315:10
Conference pass

Vaccines against EBV - Title TBC

Emerging & Re-Emerging Diseases
Chih-Jen Wei, Head of Synthetic Biology, ModeX Therapeutics
Room 202B
Apr 315:10
Conference pass

A next generation inhalation-based mucosal vaccines for COVID-19 and Flu: Potential approach to reduce infection and transmission

Clinical Trials
Room 208AB
Apr 315:10
Conference pass

High cell density and cost-effective manufacturing of viral vectors

Bioprocessing & Manufacturing
Peter Abbink, Managing Director, Batavia Biosciences
Room 209AB
Apr 315:10
Conference pass

How do we change the business model for the veterinary industry to rapidly respond to disease outbreaks?

Veterinary Vaccines and One Health
Room 204AB
Apr 315:10
Conference pass

Showcase 3: Revolutionizing Vaccine Discovery: AI-Immunology Platform for Reduced Risk and Cost in Vaccine Development

Vaccine Partnerships
Stine Friis, Director, Evaxion Biotech A/S
Room 201
Apr 315:10
Conference pass

Global Vaccine Data Network myocarditis study – new data

Vaccine Safety
Room 204C
Apr 315:10
Conference pass

From Pixels to Polio Drops: Transforming Immunization with Digital Microplans

Vaccine Supply & Logistics
Room 209C
Apr 315:25
Conference pass

Novel protein subunit technology for broad protection against SARS-CoV-2 variant

COVID & BEYOND

Reserved for Volker Gerdts, CEO & Director, VIDO

Room 207A
Apr 315:25
Conference pass

Mpox and Smallpox Vaccines: Challenges and Innovation

Emerging & Re-Emerging Diseases
Room 202B
Apr 315:25
Conference pass

Formulate the future: smart processes to ensure access to sustainable and high-performing adjuvant components: squalene and QS 21

Bioprocessing & Manufacturing
Room 209AB
Apr 315:25
Conference pass

Showcase 4: Leveraging Consortia during Preparedness and Response

Vaccine Partnerships
Room 201
Apr 315:25
Conference pass

Supporting Early-Stage Companies to Accelerate Supply Chain Innovation

Vaccine Supply & Logistics
  • Address the role of public-private partnerships to support early-stage companies that facilitate equitable access to and supply.
  • Explore the impact of BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA) in the U.S. HHS, in empowering early-stage companies to accelerate their potential solutions, including with mentorship, fee assistance, and non-dilutive funding opportunities.
  • Highlight early-stage companies aiming to disrupt supply chain and equitable access through platforms that enhance stability, accelerate participation in clinical trials, and reduce reliance of cold chain through novel distribution solutions.
Room 209C
Apr 315:40
Conference pass

Intranasal Immunization: Device and Formulation Promises and Challenges

COVID & BEYOND
Julie Suman, Vice President, Scientific Affairs, Aptar Pharma
Nektaria Karavas, Business Development Director, Aptar Pharma
Room 207A
Apr 315:40
Conference pass

Pre-clinical and clinical development, mechanisms and predictive biomarkers, of vaccines and monoclonal antibodies for opioid use disorders and overdose

Immune Profiling
Room 207B
Apr 315:40
Conference pass

Clinical pipeline updates: BioNTech

Cancer Immunotherapy
Claudia-Nanette Gann, Vice President Clinical Development, BioNTech
Room 206
Apr 315:40
Conference pass

Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines

Influenza & Respiratory
Room 202A
Apr 315:40
Conference pass

The Need for Speed: How Electronic Systems Can Accelerate Vaccine Trials

Clinical Trials

Tired of chasing data queries and spending hours correcting errors? In vaccine trials, where speed is crucial, clean data matters. This session dives into how electronic systems can revolutionize your workflow, reducing data entry errors and streamlining analysis using practical examples and case studies.

Eliminate double data entry: Put an end to double data entry and say goodbye to redundant queries with a single point of data capture.Edit-proof your data: Experience the power of automated validation and reduced manual edits, leading to cleaner, more reliable datasets.Faster analysis, faster results: Spend less time cleaning and more time analyzing, accelerating your journey to vaccine submission.

Enhance data integrity: Secure audit trails prevent unauthorized changes.

Boost your vaccine impact: Discover how clean data empowers faster development, ultimately saving lives and improving public health.

Key takeaways:

Time is of the essence in vaccine trials. This session will demonstrate how cleaner data translates to faster results, ultimately contributing to the effectiveness and broader availability of life-saving vaccines using practical case studies and real-world data.

  • Discover how electronic systems streamline data entry and reduce errors.
  • Learn how accurate data upfront saves time and resources downstream.
  • See how faster data analysis can accelerate vaccine development and availability.
Room 208AB
Apr 315:40
Conference pass

Comprehensive mRNA Vaccine Production to Accelerate into the Clinic

Bioprocessing & Manufacturing
Room 209AB
Apr 315:40
Conference pass

Big Strides in the Development of Single Shot ChAd3-based vaccines for Marburg and Sudan Virus Diseases

Vaccine Partnerships
Room 201
Apr 315:40
Conference pass

Responding to scientific and community concerns : ADEM, transverse myelitis and tinnitus

Vaccine Safety
Room 204C
Apr 315:40
Conference pass

MAPs potential and applications for LMIC

Vaccine Supply & Logistics
Room 209C
Apr 315:40
Conference pass
Apr 315:55
Conference pass

Minimizing RCA formation in large scale adenoviral vector production using CAP™ Ad cell line

Bioprocessing & Manufacturing
Room 209AB
Apr 315:55
Conference pass

Showcase 6: A unique next-generation virus-like particle vaccine candidate to protect from EBV-associated diseases

Vaccine Partnerships
Sebastian Goy, Chief Operating Officer, EBViously
Room 201
Apr 316:40
Conference pass

Avacc 10: An intranasal Outer Membrane Vesicle based subunit vaccine for COVID 19

COVID & BEYOND
Dinja Oosterhoff, VP R&D, Intravacc
Room 207A
Apr 316:40
Conference pass

Correlates of protection in the CoV002 trial of ChAdOx1.nCOV19 (Vaxzevria): A Systems Serology analysis

Immune Profiling
Room 207B
Apr 316:40
Conference pass

Clinical pipeline updates: Geneos Therapeutics

Cancer Immunotherapy
Room 206
Apr 316:40
Conference pass

Accelerate the scale-up to clinical phase: Optimizing Cell Culture Performance and Viral Vector Titers with Recombinant Insulin

Influenza & Respiratory
Chantale Julien, Product Manager, Novo Nordisk Pharmatech A/S
Room 202A
Apr 316:40
Conference pass

Block-copolymer based nanovesicles as a thermostable, non-reactive delivery platform for infectious disease vaccines

Emerging & Re-Emerging Diseases
Katherine Schultheis, Head of Discovery Research, ACM Biosciences
Room 202B
Apr 316:40
Conference pass

Leveraging Australia’s Strengths in Vaccine Clinical Trials: A Pathway to Success

Clinical Trials
Room 208AB
Apr 316:40
Conference pass

Preparing for Disease X: An Accelerated Cost-Effective Platform for Recombinant Protein Vaccine and Prophylactic Antibody Development and Manufacturing

Bioprocessing & Manufacturing
Room 209AB
Apr 316:40
Conference pass

Challenges and opportunities for mass vaccination against avian influenza: Impact on pandemic preparedness

Veterinary Vaccines and One Health
Room 204AB
Apr 316:40
Conference pass

Distributed Manufacturing Approaches for Pandemic Response and Personalized Therapy

Vaccine Partnerships
Jamie Coffin, Chief Executive Officer, Nature’s Toolbox, Inc. (NTx)
Room 201
Apr 316:40
Conference pass

Panel: Formation of public private partnerships to advance vaccine safety – priority areas for funding and research

Vaccine Safety
  • Opening remarks
  • Introduction to BECOME initiative -15min
  • Path forward for global public-private partnership on vaccine safety-10-15mins
  • Followed by panel discussion
Room 204C
Apr 316:40
Conference pass

Vaccine Risk Scores: Assessing Cold Chain Health in Real-Time

Vaccine Supply & Logistics
Room 209C
Apr 316:40
Conference pass

Can wastewater data inform vaccination campaigns for COVID-19?

Market Access
Room 203AB
Apr 316:55
Conference pass

AI-designed vaccine based on mRNA technology that protects against a broad range of betacoronaviruses

COVID & BEYOND
Kaïdre Bendjama, CSO, NEC OncoImmunity AS
Room 207A
Apr 316:55
Conference pass

A novel VLP platform technology for development of vaccines against emerging and re-emerging diseases

Emerging & Re-Emerging Diseases
Antu Dey, Senior Vice President, Preclinical R&D, Icosavax, Inc
Room 202B
Apr 316:55
Conference pass

Panel: What technologies and partnerships is industry investing in?

Vaccine Partnerships
Moderator: Hansilla Alaigh, Head of Alliances & Business Operations, Seqirus
Roman Chicz, Global Head Of External Research And Development, Sanofi
Room 201
Apr 317:10
Conference pass

Development of a broadly protective pan-sarbecovirus nanoparticle vaccine

COVID & BEYOND
Harry Kleanthous, Executive Vice President, Vaccines R&D Strategy & External Innovation, SK Bioscience
Room 207A
Apr 317:10
Conference pass

Translation & feasibility of immune correlates to the clinical space

Immune Profiling
Moderator: Lakshmi Jayashankar, Biologist, BARDA
Dan Barouch, Professor Of Medicine, Harvard Medical School
Nicole Frahm, Head of Biomarker Development, Bill & Melinda Gates Medical Research Institute
Room 207B
Apr 317:10
Conference pass

mRNA-4157 Individualized Neoantigen Therapy: mRNA therapeutics coming of age in cancer

Cancer Immunotherapy
Room 206
Apr 317:10
Conference pass

Influenza Virus reverse genetics for vaccine and assay development

Influenza & Respiratory
Room 202A
Apr 317:10
Conference pass

Optimised Prime: A Transformative RNA-LNP Vaccine Composition that Scales

Emerging & Re-Emerging Diseases
Martin Rabel, Services Solutions Specialist, Cytiva
Room 202B
Apr 317:10
Conference pass

Rapid development of lyophilized VLP-Nucleic acid vaccines – Title TBC

Bioprocessing & Manufacturing
Prabuddha Kundu, Cofounder & Managing Director, Premas Biotech
Room 209AB
Apr 317:10
Conference pass

Anti-tick Immunomodulator – for Biological Control of One-Host Ticks in Cattle

Veterinary Vaccines and One Health
Room 204AB
Apr 317:10
Conference pass

Digitalization of Vaccine Supply Chains

Vaccine Supply & Logistics
Bill Mcgillian, Associate Engineering Director, Merck
Room 209C
Apr 317:25
Conference pass

Liposome display of recombinant antigens: A versatile approach for coronavirus vaccines

COVID & BEYOND
Room 207A
Apr 317:40
Conference pass

Novel combined mRNA vaccines against Covid, flu and RSV

COVID & BEYOND

Reserved for Dr Wassana Wijagkanalan, Scientific Advisor, BioNet

Room 207A
Apr 317:40
Conference pass

Development of Neoantigen Vaccines for Cancer – Title TBC

Cancer Immunotherapy
Room 206
Apr 317:40
Conference pass

Title TBC

Influenza & Respiratory

Senior representative Vaxess

Room 202A
Apr 317:40
Conference pass

6-Valent, OspA-based Lyme Disease Vaccine (VLA15) - Clinical Development Overview

Emerging & Re-Emerging Diseases
Eduardo Forleo-Neto, VP, Vaccine Clinical Research & Development, Pfizer
Apr 317:40
Conference pass

Vaccine Formulations Applications, related Functionalities and Performance in Biologic Drug Product

Bioprocessing & Manufacturing
Room 209AB
Apr 317:40
Conference pass

First Infectious Disease Monoclonal antibodies to defeat canine parvo and defend puppies!

Veterinary Vaccines and One Health
Room 204AB
Apr 317:40
Conference pass

Investment Panel: how to secure funding for vaccines for global health?

Vaccine Partnerships
Mario Barro, Director of Innovation, Vaccines, RA Capital
Kabeer Aziz, Co-Founder & Principal, Adjuvant Capital
Room 201
Apr 317:40
Conference pass

Supporting Domestic Manufacturing Capacity: Government-Industry Working Session

Vaccine Supply & Logistics

Domestic manufacturing in the U.S. healthcare supply chain is essential for ensuring a resilient and responsive system, especially in times of crisis. Supporting local or regionalized production reduces sourcing risks, ensuring timely and reliable access to critical healthcare supplies, and an economically sound medical/pharmaceutical industrial base. This session provides an opportunity for interactive dialogue with federal partners on long term solutions.

Room 209C
Apr 317:55
Conference pass

A broadly protective Betacoronavirus vaccine using mRNA platform technology

COVID & BEYOND
Jonathan Heeney, Chief Executive Officer, DIOSynVax Limited
Room 207A
Apr 317:55
Conference pass

Self-assembling in-vivo nano particle vaccines

Influenza & Respiratory
Room 202A
Apr 317:55
Conference pass

Re-emerging diseases, Anthrax rises from the dust: Results from the Phase 3 Clinical Trial of the Novel CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine for Post-Exposure Prophylaxis of Inhala

Emerging & Re-Emerging Diseases
Room 202B
Apr 317:55
Conference pass

A Live Attenuated Vaccine for Foot and Mouth Disease

Veterinary Vaccines and One Health
Steffen Mueller, Chief Scientific Officer, Codagenix Inc.
Room 204AB
Apr 318:10
Conference pass

Revolutionizing Viral Vaccine Production: Unleashing the Power of Scale-X Fixed Bed Bioreactors for Next-Gen Viral Vaccine Manufacturing

Bioprocessing & Manufacturing
Room 209AB
Apr 318:15
Conference pass

Off-site Networking Drinks

Networking Drinks

Sponsored by Viroclinics-DDL

Cuba Libre, 801 9th St NW

Create your personal agenda –check the favourite icon

Apr 49:00
Conference pass

Chair's Opening Remarks

COVID & BEYOND
Bassam Hallis, Deputy Director, Research and Evaluation, UK Health Security Agency
Room 207A
Apr 49:00
Conference pass
Apr 49:00
Conference pass

Chair's Opening Remarks

Cancer Immunotherapy
Room 206
Apr 49:00
Conference pass

Chair's opening remarks

Emerging & Re-Emerging Diseases
Room 202B
Apr 49:00
Conference pass
Apr 49:00
Conference pass

Chair's Opening Remarks

Bioprocessing & Manufacturing
Michael Chaplet, Comparability & Characterisation Lead, MSAT Analytical and Material Science, GSK
Room 209AB
Apr 49:00
Conference pass

Chair's Opening Remarks

Veterinary Vaccines and One Health
Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Room 204AB
Apr 49:00
Conference pass

Chair's opening remarks

Vaccine Partnerships
Philippa Harvey, Director - COVID Vaccines Unit, UK Health Security Agency
Room 201
Apr 49:00
Conference pass

Chair's Opening Remarks

Vaccine Safety
Room 204C
Apr 49:00
Conference pass

Chair's Opening Remarks

Vaccine Supply & Logistics
Room 209C
Apr 49:00
Conference pass

Chair's Opening Remarks

Market Access
Room 203AB
Apr 49:05
Conference pass

Panel: Progress towards eliminating Malaria

Emerging & Re-Emerging Diseases

-Do we need multi-stage vaccine vs multi target vaccines?

-Elimination vs Eradication

-What are the biggest hurdles to enable malaria vaccine eradication?

Moderator: Chandresh Harjivan, Special Assistant to the President, Domestic Preparedness and Response to Biological Threats, Office of Pandemic Preparedness and Response Policy (OPPR), Executive Office of The President (EOP)
Stephen Hoffman, Chief Executive And Scientific Officer, Sanaria
Miriam Laufer, Professor of Pediatrics Malaria Research Program Director, University Of Maryland, Center For Vaccine Development and Global Health
Room 202B
Apr 49:10
Conference pass

Development of a broadly reactive multispecific COVID antibody

COVID & BEYOND
Room 207A
Apr 49:10
Conference pass

Advancement of Human In vitro Modeling for the identification of vaccine formulations tailored towards vulnerable populations

Immune Profiling
Room 207B
Apr 49:10
Conference pass

Combinations of vaccines with novel immunomodulatory agents beyond checkpoint inhibitors

Cancer Immunotherapy
Room 206
Apr 49:10
Conference pass

So what’s next? Respiratory viruses we need to think about in the future

Influenza & Respiratory
Room 202A
Apr 49:10
Conference pass

Redefining patient recruitment in vaccine trials: A data-driven, diverse, and transparent approach

Clinical Trials
Cynthia Dukes, Site and Medical Operations, Avacare
Room 208AB
Apr 49:10
Conference pass

Manufacturing Solutions for Production of First Clinical Trial Material for Biologics

Bioprocessing & Manufacturing
Room 209AB
Apr 49:10
Conference pass

Antigen screening for Border Disease RNA Vaccines

Veterinary Vaccines and One Health
Room 204AB
Apr 49:10
Conference pass

Panel: How we can leverage and secure US government R&D funding from domestic agencies (HHS, DoD, etc) to spur vaccine development and better distribution?

Vaccine Partnerships
Room 201
Apr 49:10
Conference pass

How to promote confidence in vaccines (and undo misinformation) in your social circles & communities Dr Michael Miller, Health Care Communications & Policy Consultant, HealthPolCom

Vaccine Safety
Room 204C
Apr 49:10
Conference pass

COVAX, what’s next?

Vaccine Supply & Logistics
  • What did we learn from COVAX during COVID and how are we preparing for rapid roll out of vaccines in future pandemics and epidemics?
  • Vaccine supply chain considerations for multi stakeholder collaboration and contingency planning for future disease outbreaks.
  • Strengthening end-to-end capabilities during non-pandemic periods, to create a resilient ecosystem for future emergency situations.
Room 209C
Apr 49:10
Conference pass

Creating a sustainable vaccine ecosystem: successes, gaps and opportunities

Market Access
Room 203AB
Apr 49:25
Conference pass

Improving genetic tools for African swine fever virus to facilitate development of an effective vaccine

Veterinary Vaccines and One Health
Room 204AB
Apr 49:40
Conference pass
Apr 49:40
Conference pass

High throughput tracking of neutralizing antibodies and antigen-specific clonal expansion in nonhuman primates immunized against HIV envelope.

Immune Profiling
Room 207B
Apr 49:40
Conference pass

New Frontiers in Cancer Vaccine Antigens: AI-Driven Target Discovery for Broader Therapeutic Reach

Cancer Immunotherapy
Room 206
Apr 49:40
Conference pass

Update on Pneumococcal vaccine

Influenza & Respiratory
Tamara Pilishvili, Medical Director, US Medical and Clinical Affairs Lead, Pneumococcal MAPS Vaccines, GSK
Room 202A
Apr 49:40
Conference pass

Improving Clinical Trial Recruitment

Clinical Trials
Room 208AB
Apr 49:40
Conference pass

Developing a Smart, Digitally Controlled, Fully Integrated Continuous Manufacturing Production Line designed for Pandemic-Level Response

Bioprocessing & Manufacturing
Room 209AB
Apr 49:40
Conference pass

Creating access to clinical developments for neglected populations of the world, fighting against vaccine scarcity in LMICs

Market Access
Room 203AB
Apr 49:55
Conference pass

M2SR & Next Gen Respiratory Vaccines

COVID & BEYOND
Paul Radspinner, Chief Executive Officer, FluGen Inc
Room 207A
Apr 49:55
Conference pass

Panel: Medical Countermeasures for Ebola & other emerging infectious diseases: Are we ready?

Emerging & Re-Emerging Diseases

Room 202B
Apr 49:55
Conference pass

Matrix Collection Provisionss to Enable Successful Immunological Testing for Global Vaccine Clinical Trials

Clinical Trials
Thomas Beadnell, Associate Scientific Advisor, Eurofins Viracor BioPharma
Room 208AB
Apr 49:55
Conference pass

The first anti fungal vaccine-A solution for both ends of the leash

Veterinary Vaccines and One Health
Room 204AB
Apr 410:00
Conference pass

What is a Sustainable Posture for Biodefense, Biosecurity, and Global Health Security?”

Vaccine Supply & Logistics
Room 209C
Apr 410:10
Conference pass

Cutaneous jet injection of naked mRNA for safe and effective vaccination against infectious diseases

COVID & BEYOND
Satoshi Uchida, Professor, Tokyo Medical and Dental University (TMDU)
Room 207A
Apr 410:10
Conference pass

Binding characterization of viral targets and immunotherapeutics with Digital SPR

Immune Profiling
Room 207B
Apr 410:10
Conference pass

Oncolytic Virotherapy: Overcoming Hurdles in the Realm of mRNA Vaccines

Cancer Immunotherapy
Room 206
Apr 410:10
Conference pass

Recombinant vaccine against pertussis resurgence and for maternal immunization

Influenza & Respiratory
Room 202A
Apr 410:10
Conference pass

Title TBC

Clinical Trials

Senior Representative, Cepheid

Room 208AB
Apr 410:10
Conference pass

Expansion of the Industrial Manufacturing Base for Medical Countermeasures

Bioprocessing & Manufacturing
Brooke Luck, BioMaP Program Manager, BARDA
Room 209AB
Apr 410:10
Conference pass

Nanoscale liposomal GD3 vaccine stimulates an immune response in naturally occuring cancers in canines

Veterinary Vaccines and One Health
Room 204AB
Apr 410:10
Conference pass

Vaccine Innovation: The Path to Global Health Resilience

Vaccine Partnerships
Moderator: Candice Decaire, Chief Strategy Officer / General Counsel, Access to Advanced Health Institute
Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
José Castillo, Chief Executive Officer, Quantoom Biosciences
Kyle McGowan, Access to Advanced Health Institute
Room 201
Apr 410:10
Conference pass

Catch up and recovery efforts in LMICS – have we seen the progress expected?

Market Access
Room 203AB
Apr 410:25
Conference pass

Vaccines Evaluation: Serological assays for Viruses & Respiratory Diseases

Influenza & Respiratory
Alessandro Manenti, Chief Development Officer, VisMederi Research Srl
Room 202A
Apr 410:25
Conference pass

I Knew You Were Trouble: Overcoming Barriers in Clinical Trial Recruitment

Clinical Trials
Room 208AB
Apr 410:40
Conference pass

Networking Break

Exhibition Hall
Exhibition Hall D, Level 2
Apr 411:30
Conference pass

The development of multi-epitope, nanoparticle-based vaccine candidates that could provide broad protection against SARS-CoV-2 variants and other Betacoronaviruses

COVID & BEYOND
Room 207A
Apr 411:30
Conference pass

Overcoming original antigenic sin

Immune Profiling
  • Molecular determinants of antigenic evolution & immunological mechanisms of OAS
  • Implications on vaccine design & immunization strategies: combined resp virus vaccines?
  • Strategies to overcome or minimize impacts of OAS
Moderator: Rosemary Bastian, Director, Translational Science, BioNTech SE
Laura Walker, Head, Infectious Disease Biotherapeutics Discovery & Engineering, Moderna
Patrick Wilson, Anne E. Dyson Professor of Pediatric Research, Weill Cornell Medical College, Cornell University
Elodie Ghedin, Senior Investigator, National Institute of Health - NIAID
Room 207B
Apr 411:30
Conference pass

GD3 and GD2 gangliosides serve as tissue-agnostic cancer antigens in a nano-scale liposomal cancer vaccine in a true disease model of osteosarcoma and melanoma

Cancer Immunotherapy
Room 206
Apr 411:30
Conference pass

Panel: The future of novel Pneumococcal Vaccines

Influenza & Respiratory
Room 202A
Apr 411:30
Conference pass

Panel: Dengue – Challenges and opportunities in Vaccine development

Emerging & Re-Emerging Diseases
  • Arthropod-borne viruses: Chikungunya, Dengue, Eastern equine encephalitis
Moderator: Anna Durbin, Professor, Johns Hopkins Bloomberg School of Public Health
Adam Waickman, Associate Professor, SUNY Upstate Medical University
Room 202B
Apr 411:30
Conference pass

Enhancing Clinical Trials with Scalable, Reproducible and Robust T-Cell Testing from Fresh Blood

Clinical Trials
Room 208AB
Apr 411:30
Conference pass

Accelerating mRNA and LNP Manufacturing with Platform Analytical and Process Technologies

Bioprocessing & Manufacturing
Room 209AB
Apr 411:30
Conference pass

How will new technology platform and innovation strategy accelerate Veterinary Vaccine development?

Veterinary Vaccines and One Health
  • How are we considering and accelerating the development of new technologies for adjuvants, antigen discovery, stability and delivery in Veterinary Vaccine and therapies?
  • Is there a place for academic innovation and how will can this be translated to into vaccine development?
  • How are we exploring the use of RNA technology for farm animals?
  • What are the remaining challenges for RNA vaccines in the veterinary industry: price, delivery?

Room 204AB
Apr 411:30
Conference pass

Panel: How we teach about vaccines and vaccination

Vaccine Partnerships
Room 201
Apr 411:30
Conference pass

Strategies for building successful trusted messaging around vaccines

Vaccine Safety
  • Panelists will share their specific programs for vaccination education and adoption
  • Discuss how their approach is working for the populations they serve and the challenges that remain
  • Discuss lessons learned in their educational efforts that others could use in their programs
Room 204C
Apr 411:30
Conference pass

Building healthcare supply chains to support regional production on the African Continent

Vaccine Supply & Logistics
Room 209C
Apr 411:30
Conference pass

Digital accessibility & improving access to vaccines for underserved populations *title TBC

Market Access
Room 203AB
Apr 411:45
Conference pass

Early stage clinical results from a novel preventative breast cancer vaccine – Title TBC

Cancer Immunotherapy
Room 206
Apr 411:45
Conference pass

Lyo No More: A Step Away from Traditional Fill/Finish Processes and Into the Future

Bioprocessing & Manufacturing
Room 209AB
Apr 412:00
Conference pass

Vaccine induction of broadly-specific antibody and T-cell responses to combat SARS-CoV-2 variation

COVID & BEYOND
Room 207A
Apr 412:00
Conference pass

Tissue-targeted lipid nanoparticle delivery for mRNA encoding bispecific T-cell engager demonstrated potent antitumor effects on both hematological malignancies and solid tumors – Title TBC

Cancer Immunotherapy
Kate Zhang, Chief Scientific Officer, Hopewell Therapeutics
Room 206
Apr 412:00
Conference pass

Outstanding Clinical Performance from a Next Generation srRNA vaccine

Clinical Trials
Room 208AB
Apr 412:00
Conference pass

Innovations & Technologies for the Last Mile

Vaccine Supply & Logistics
Room 209C
Apr 412:00
Conference pass

Fireside chat –New approaches /ways of thinking about vaccine equity initiatives *Title TBC

Market Access

· Engaging with diverse partners to encourage vaccination in underserved communities

· Innovative initiatives with trusted partners

· Addressing emerging needs and changing demographics

· Overcoming challenges in your own communities

Room 203AB
Apr 412:15
Conference pass

Unmet Vaccine Needs and Trial Challenges in Low and Middle-Income Countries

Clinical Trials
Room 208AB
Apr 412:15
Conference pass

Accelerating vaccine development and manufacturing using a flexible and scalable cell programming platform

Bioprocessing & Manufacturing
Room 209AB
Apr 413:30
Conference pass

Plenary chair’s opening remarks

Keynotes
Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Keynote, Hall D
Apr 413:40
Conference pass

Keynote Panel: Escalating infections: the impact of climate change and natural disasters on infectious diseases

Keynotes
  • Which world vaccination programs are under threat?
  • The devasting impact on infectious diseases reaching far beyond its origins
  • How climate change increases pandemic risk and spillover between humans and animals
  • The need to invest in strong health systems now to stay resilient to the inevitable complex changes that climate change will bring
Bruce Gellin, SVP and Chief, Global Public Health Strategy, The Rockefeller Foundation
Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
Keynote, Hall D
Apr 414:30
Conference pass

Keynote closing panel: The impact on AI to protecting public health threats and behaviour

Keynotes
  • The role of AI in public health, current and future
  • Could AI have helped us to prevent a pandemic? Expanding vaccine libraries, predicting strain drifts, monitoring surveillance, vaccine design
  • How to use AI to improve early warning signals and quickly target identify new targets that have no countermeasures
  • Success, limitations and risks of AI
  • What is the evolving regulatory landscape on AI?
  • Biosecurity considerations and the future of infectious diseases/biodefence vaccines
Keynote, Hall D
Apr 415:20
Conference pass

A World Without Cervical Cancer: How The Power of Vaccines Can Help Achieve This Goal?

Keynotes
Keynote, Hall D
Apr 415:40
Conference pass

Chair Closing Remarks and End of Congress

Keynotes
Gregory Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Keynote, Hall D
last published: 18/Mar/24 22:25 GMT